Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | NEU4 | Q8WWR8 | 1/20 | 0.39 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | DDX3X | O00571 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13878324 | 0.86 | CYP19A1 (0.51) | POLBKMT2AALDH1A1CYP19A1GGPS1 | |
| SCHEMBL23038420 | 0.84 | POLB (0.57) | POLBKMT2ANEU4NEU3ALDH1A1 | |
| SCHEMBL21626004 | 0.83 | POLB (0.47) | POLBKMT2AALOX5NEU4NEU3 | |
| SCHEMBL18235987 | 0.82 | POLB (0.38) | POLBKMT2AALDH1A1CYP19A1GGPS1 | |
| SCHEMBL13437076 | 0.82 | FOLH1 (0.46) | POLBKMT2AALDH1A1HDAC1GGPS1 | |
| SCHEMBL24276636 | 0.82 | HDAC1 (0.48) | ALDH1A1HDAC1 | |
| SCHEMBL24276661 | 0.81 | EPHX2 (0.47) | ALDH1A1HDAC1 | |
| SCHEMBL15257805 | 0.81 | MAOA (0.43) | POLBKMT2AALDH1A1GGPS1 | |
| SCHEMBL16891850 | 0.81 | POLB (0.38) | POLBKMT2AALDH1A1HDAC1 | |
| SCHEMBL25836729 | 0.79 | SRC (0.38) | POLBKMT2AALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | POLB 870/4885KMT2A 2610/4885ALOX5 615/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | POLB 870/4885KMT2A 2610/4885ALOX5 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.